Influenza Treatment Global Market Report 2024

The influenza treatment market size has grown steadily in recent years. It will grow from $6.34 billion in 2023 to $6.6 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increased government funding for influenza research and preparedness programs, growth in the number of annual influenza cases, the establishment of global influenza surveillance systems, public awareness campaigns promoting vaccination, and growth in healthcare facilities.

The influenza treatment market size is expected to see steady growth in the next few years. It will grow to $7.83 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The anticipated growth during the forecast period can be credited to the introduction of novel antiviral medications and treatment approaches, the expansion of vaccination initiatives, ongoing enhancement and enlargement of healthcare infrastructure, a rising elderly population, and the advancement of new treatments. Key trends expected in this period involve advancements in the development of universal vaccines, innovations in vaccine delivery mechanisms, the integration of AI and big data, progress in personalized medicine, and heightened collaborations between pharmaceutical firms.

The rising incidence of contagious respiratory illnesses is anticipated to drive the influenza treatment market forward. Contagious respiratory illnesses encompass infectious diseases such as influenza, measles, or respiratory syncytial virus (RSV) infections, which spread through contact with infected individuals or their bodily fluids, contaminated surfaces, or objects. Factors fueling the increase in contagious respiratory illnesses include higher population densities, inadequate healthcare infrastructure, misuse of antibiotics, and facilitated international travel. Influenza treatment involves the use of antiviral drugs and vaccinations to manage various contagious respiratory illnesses such as flu, COVID-19, and other respiratory viruses. For example, in September 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the hospitalization rate associated with RSV (Respiratory Syncytial Virus) rose from 2 hospitalizations per 100,000 individuals during the week ending August 5, 2023, to 7 hospitalizations per 100,000 individuals by the week ending on August 19, 2023. Hence, the increased prevalence of contagious respiratory illnesses is propelling the growth of the influenza treatment market.

Prominent companies in the influenza treatment market are concentrating on broadening their product range by introducing innovative solutions, such as single-dose oral medication for influenza treatment, with the aim of enhancing patient adherence, improving treatment outcomes, and securing a larger market share. A single-dose oral medication is a drug formulated to address influenza (flu) with just one oral dose, simplifying the treatment regimen. For example, in August 2022, Genentech Inc., a US-based biotechnology company, revealed the U.S. Food and Drug Administration (FDA) approval for Xofluza (Baloxavir Marboxil). Xofluza stands as the premier and sole single-dose oral medication, providing a convenient and effective solution for managing acute uncomplicated influenza in children aged five to less than 12 years who have exhibited symptoms for no more than 48 hours, as well as other respiratory viruses.

In June 2022, Pfizer Inc., a pharmaceutical company headquartered in the United States, purchased ReViral for an undisclosed sum. This acquisition is aimed at broadening Pfizer's product portfolio by incorporating one of the therapeutic candidates, Sisunatovir, which is an orally administered inhibitor designed to specifically impede the fusion of the respiratory syncytial virus (RSV) with the host cell. ReViral is a biotechnology company based in the United Kingdom, known for its development and provision of innovative therapies for viral diseases.

Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd, Dr. Reddy's Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.

North America was the largest region in the influenza treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the influenza treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Influenza treatment involves medical measures intended to manage and relieve symptoms, shorten the duration of illness, and prevent complications linked to influenza virus infections. It includes antiviral drugs and supportive care aimed at alleviating flu symptoms, shortening the illness duration, and averting severe complications.

The primary products employed for treating influenza include peramivir, zanamivir, oseltamivir phosphate, baloxavir marboxil, and others. Peramivir is an antiviral drug utilized for influenza treatment. These medications can be administered via various routes, including orally and others, and are available through different distribution channels, such as retail pharmacies, hospital pharmacies, and others.

The influenza treatment market research report is one of a series of new reports that provides influenza treatment market statistics, including influenza treatment industry global market size, regional shares, competitors with a influenza treatment market share, detailed influenza treatment market segments, market trends and opportunities, and any further data you may need to thrive in the influenza treatment industry. This influenza treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The influenza treatment market consists of sales of ibuprofen, dextromethorphan, acetaminophen, and nasal sprays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.